HRS-2183

HRS-2183 is an investigational injectable drug being developed by Jiangsu Hengrui Pharmaceuticals. It is currently in early-stage clinical development, with studies primarily focusing on evaluating its safety, tolerability, and pharmacokinetic profile in healthy adult subjects. As of early 2025, the specific biological target and mechanism of action for HRS-2183 have not been publicly disclosed by the developer, which is consistent with the proprietary nature of many early-phase assets in the Hengrui pipeline. The drug is administered via injection and is undergoing both single-dose and multiple-dose ascending studies to establish its clinical profile.